Caricamento...
Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo
Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds. Multidrug therapies achieve pathological cure rates of only 20–40%, a consequence of dr...
Salvato in:
| Pubblicato in: | Oncol Res |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Cognizant Communication Corporation
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7751225/ https://ncbi.nlm.nih.gov/pubmed/32430093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504020X15898794315356 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|